Yttrium 90-labelled edotreotide(Yttrium 90-labelled edotreotide) - 药物靶点：SSTR_在研适应症：神经内分泌肿瘤_专利_临床

概要

基本信息

药物类型

多肽偶联核素、治疗用放射药物

别名

90Y-DOTA-D-Phe1-Tyr3-octreotide、OctreoTher、Onalta

+ [7]

靶点

SSTR

作用机制

SSTR激动剂(生长抑素受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

University of IowaNovartis Pharma AG

非在研机构

Molecular Insight Pharmaceuticals, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C65H89N14O18S2Y

InChIKeyDUSFGVAHRFYHFD-IEOVAKBOSA-K

CAS号189758-25-6

序列信息

Sequence Code 526980110

来源: *****

关联

9

项与 Yttrium 90-labelled edotreotide 相关的临床试验

NCT03724409 / Terminated早期临床1期

Selective Intra-arterial Injection of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumor Patients With Liver Metastases

This is a safety study to determine the phase 1 starting dose of [90]Yttrium-DOTATOC when it is administered intravenously for patients with neuroendocrine tumors that have spread to the liver.

开始日期2018-10-11

申办/合作机构

University of Iowa

[+3]

NCT03197012 / Completed早期临床1期IIT

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 90Y-DOTA-TOC via the hepatic artery.
Participants in the correlative sub-study will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose, and undergo additional imaging and assessment.

开始日期2017-07-01

申办/合作机构

The University of California, San Francisco

NCT03044977 / Active, not recruiting早期临床1期

Phase 1 Trial Using 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors.

This study is designed to identify the best tolerated doses of [131]Iodine-MIBG and [90]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated doses of these drugs (when combined together) is unknown.

开始日期2017-05-07

申办/合作机构

University of Iowa

[+3]

100 项与 Yttrium 90-labelled edotreotide 相关的临床结果

登录后查看更多信息

100 项与 Yttrium 90-labelled edotreotide 相关的转化医学

登录后查看更多信息

100 项与 Yttrium 90-labelled edotreotide 相关的专利（医药）

登录后查看更多信息

125

项与 Yttrium 90-labelled edotreotide 相关的文献（医药）

2024-07-01·Journal of vascular and interventional radiology : JVIR

Outcomes in Patients with Macrotrabecular-Massive Subtype Hepatocellular Carcinoma Treated with Yttrium-90 Transarterial Radioembolization

Article

作者: Sozutok, Sinan ; Balli, Huseyin Tugsan ; Aikimbaev, Kairgeldy ; Erdoğan, Kivilcim Eren ; Piskin, Ferhat Can

PURPOSE:

To compare the outcomes of yttrium-90 transarterial radioembolization (TARE) in patients with hepatocellular carcinoma (HCC) with and without macrotrabecular-massive (MTM) subtypes.

MATERIALS AND METHODS:

Forty-one consecutive patients with HCC (male, 90.3%; mean age, 65.3 years [SD ± 10.7]) who underwent yttrium-90 TARE between September 2014 and January 2022 were grouped into the MTM-HCC (n = 17, 41.5%) and non-MTM-HCC (n = 24, 58.5%) groups based on their histopathological subtypes. Demographic, clinical, and radiological characteristics were compared. Survival, univariate, and multivariate analyses were performed, and prognostic factors were evaluated.

RESULTS:

In MTM-HCC group, the rates of moderately to poorly differentiated tumors were significantly higher (13/17 vs 8/16, P = .007), and new intrahepatic/extrahepatic metastases were detected more frequently (12/17 vs 15/24, P = .038). Median overall survival (OS) in the cohort was 29 months (range, 17.1-40.9 months), whereas patients with MTM-HCC had a significantly shorter median OS (20 vs 44 months, P = .014). In univariate analysis, MTM-HCC subtype (hazard ratio [HR], 2.690; P = .021), the presence of satellite nodules (HR, 3.810; P = .004), and macrovascular invasion (HR, 3.321; P = .012) were identified as significant prognostic factors. In multivariate analysis, MTM-HCC subtype and macrovascular invasion were determined as independent poor prognostic factors (P = .038 and P = .012, respectively).

CONCLUSIONS:

In patients with HCC treated with yttrium-90 TARE, both the rates of moderately to poorly differentiated histopathological classes and the development of intrahepatic or extrahepatic metastases were significantly higher in the MTM-HCC subtype. OS was worse in patients with MTM-HCC, and macrovascular invasion and MTM-HCC subtype were identified as independent poor prognostic factors.

2023-09-01·Journal of neuro-oncology

Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.

Article

作者: Beliveau, Vincent ; Gizewski, Elke R ; Iglseder, Anna ; Scherfler, Christoph ; Heugenhauser, Johanna ; Stockhammer, Guenther ; Uprimny, Christian ; Nowosielski, Martha ; Kerschbaumer, Johannes ; Dudas, Jozsef ; Nevinny-Stickel, Meinhard ; Virgolini, Irene ; Iglseder, Sarah

OBJECTIVE:

This retrospective study aimed to analyse the correlation between somatostatin receptor subtypes (SSTR 1-5) and maximum standardized uptake value (SUV_max) in meningioma patients using Gallium-68 DOTA-D-Phe1-Tyr3-octreotide Positron Emission Tomography ([68Ga]Ga-DOTATOC PET). Secondly, we developed a radiomic model based on apparent diffusion coefficient (ADC) maps derived from diffusion weighted magnetic resonance images (DWI MRI) to reproduce SUV_max.

METHOD:

The study included 51 patients who underwent MRI and [68Ga]Ga-DOTATOC PET before meningioma surgery. SUV_max values were quantified from PET images and tumour areas were segmented on post-contrast T1-weighted MRI and mapped to ADC maps. A total of 1940 radiomic features were extracted from the tumour area on each ADC map. A random forest regression model was trained to predict SUV_max and the model's performance was evaluated using repeated nested cross-validation. The expression of SSTR subtypes was quantified in 18 surgical specimens and compared to SUV_max values.

RESULTS:

The random forest regression model successfully predicted SUV_max values with a significant correlation observed in all 100 repeats (p < 0.05). The mean Pearson's r was 0.42 ± 0.07 SD, and the root mean square error (RMSE) was 28.46 ± 0.16. SSTR subtypes 2A, 2B, and 5 showed significant correlations with SUV_max values (p < 0.001, R2 = 0.669; p = 0.001, R2 = 0.393; and p = 0.012, R2 = 0.235, respectively).

CONCLUSION:

SSTR subtypes 2A, 2B, and 5 correlated significantly with SUV_max in meningioma patients. The developed radiomic model based on ADC maps effectively reproduces SUV_max using [68Ga]Ga-DOTATOC PET.

2023-05-01·Clinical nuclear medicine

Differentiation of a Falcine Meningioma From Cerebral Venous Sinus Thrombosis Using DOTATATE PET

Article

作者: Neuneier, Janina ; Galldiks, Norbert ; Fink, Gereon R ; Drzezga, Alexander ; Schlamann, Marc ; Werner, Jan-Michael ; Stetter, Isabelle ; Baumann, Claudia ; Schmidt, Matthias ; Schroeter, Michael

Abstract:

Differentiating brain tumors from nonneoplastic lesions using conventional MRI may be challenging. Clinical symptoms often remain unspecific, and imaging findings from MRI may be inconclusive. We present the case of a 23-year-old woman in whom an MRI suggested a cerebral venous sinus thrombosis. On the other hand, additional atypical MRI findings raised doubts regarding the initial diagnosis. Given the need for a diagnostic procedure with higher sensitivity and specificity for neoplastic tissue, PET with the radiolabeled somatostatin receptor ligand DOTATATE (68Ga-DOTA-d-Phe1-Tyr3-octreotate) was performed. DOTATATE PET facilitated the diagnosis of a falcine meningioma consistent with its value for the differential diagnosis of meningioma.

100 项与 Yttrium 90-labelled edotreotide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
消化道恶性类癌	临床2期	-	Molecular Insight Pharmaceuticals, Inc.	2008-06-01
神经内分泌肿瘤	临床2期	-	University of Iowa	-
神经内分泌肿瘤	临床2期	-	Novartis Pharma AG	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2004	N/A	神经内分泌肿瘤	60	[Y-90-DOTA,Tyr3]octreotide (4-cycle regimen)	襯艱繭遞壓衊鏇壓夢餘(鏇襯鹹鑰壓願糧膚齋鏇) = 夢構糧廠獵顧鑰顧窪簾顧膚選鑰壓齋鑰夢蓋膚 (製壓願鹹憲鬱窪觸觸膚, 38% less than baseline) 更多	-	2004-07-15
				[Y-90-DOTA,Tyr3]octreotide (single-cycle regimen)	襯艱繭遞壓衊鏇壓夢餘(鏇襯鹹鑰壓願糧膚齋鏇) = 鏇壓繭鬱鏇鬱網夢鹹製顧膚選鑰壓齋鑰夢蓋膚 (製壓願鹹憲鬱窪觸觸膚, 27% less than baseline) 更多